Big Pharma's $53B Feeding Frenzy Just Started

And most investors have no idea what's happening...

The numbers:

→ Pfizer: $43B
→ AbbVie: $10.1B
→ Target: ADC technology

This isn’t slowing down. It’s accelerating.

Antibody-drug conjugates are reshaping cancer treatment. Precision medicine that actually works at scale. The FDA is greenlighting approvals. Multi-billion dollar revenues are flowing.

And Big Pharma can’t build fast enough—so they’re buying everything in sight.

But here’s what matters for your portfolio...

The companies getting acquired aren’t the only opportunity. Platform technology firms solving critical delivery challenges are commanding valuations that rival approved drugs.

The question is: How long before those disappear too?

-Christopher

P.S. Don’t wait for the next $40B headline. See which companies Big Pharma is targeting next →